Ticker Details
BioMarin Pharmaceutical Inc. Biomarin Pharmaceutical Inc is on rare-disease therapies. It develops and commercializes pharmaceuticals for serious diseases and medical conditions.
IPO Date:	August 1, 1999
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$12.91B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.95 | 1.76%
Avg Daily Range (30 D):	$1.08 | 1.71%
Avg Daily Range (90 D):	$0.95 | 1.65%

Institutional Daily Volume
Avg Daily Volume:	1.23M
Avg Daily Volume (30 D):	1.61M
Avg Daily Volume (90 D):	1.61M

Trade Size
Avg Trade Size (Sh.):	100
Avg Trade Size (Sh.) (30 D):	57
Avg Trade Size (Sh.) (90 D):	58

Institutional Trades
Total Institutional Trades:	25,005
Avg Institutional Trade:	$3.68M
Avg Institutional Trade (30 D):	$6.94M
Avg Institutional Trade (90 D):	$5.65M
Avg Institutional Trade Volume:	.06M
Avg Institutional Trades (Per Day):	5

Market Closing Trades
Avg Closing Trade:	$11.55M
Avg Closing Trade (30 D):	$22.47M
Avg Closing Trade (90 D):	$21.54M
Avg Closing Volume:	151.06K

News

May 26, 2026 @ 5:00 PM Duchenne Muscular Dystrophy Clinical Trial Pipelin... Source: Delveinsight

May 21, 2026 @ 6:11 PM BioMarin Reveals Dwarfism Study Data, Stock Soars Source: Vandana Singh

Apr 25, 2026 @ 3:13 PM CIBRA Capital Makes a Big Merger Arbitrage Bet On ... Source: Cory Renauer

Mar 20, 2026 @ 4:07 PM Biotech Stock Up 372% Gets Sold as New Pick Rises ... Source: Jonathan Ponciano

Mar 17, 2026 @ 12:00 AM This Investor Sold $104 Million of Nuvalent Stock ... Source: Jonathan Ponciano

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$.38	$.23	$.55
Diluted EPS	$.37	$.23	$.54
Revenue	$3.41B	$989.71M	$766.21M
Gross Profit	$2.59B	$786.91M	$571.21M
Net Income / Loss	$72.97M	$44.76M	$105.53M
Operating Income / Loss	$149.26M	$110.92M	$129.64M
Cost of Revenue	$813.59M	$202.8M	$195M
Net Cash Flow	$-340.14M	$-2195.39M	$1.76B
PE Ratio